Knowledge gaps regarding human papillomavirus vaccine implementation in ordinary vaccination schedules;Interrogantes en la introducción de la vacuna frente al virus del papiloma humano en los calendarios sistemáticos

Medicina Clinica

Volumn 129, Issue 2, 2007, Pages 55-60

  Navarro Alonso, José A ^a   Bernal González, Pedro J ^a   Pérez Martín, Jaime J ^a  

^a Programas de Salud Infantil y Juvenil   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; CANCER INCIDENCE; CANCER PREVENTION; CARCINOMA IN SITU; HUMAN; IMMUNIZATION; INFECTION CONTROL; INFECTION PREVENTION; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; VIRUS INFECTION; VIRUS VIRULENCE; WART VIRUS;

EID: 34548557259     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1157/13106938     Document Type: Article

References (50)

1. Muñoz N, Bosch X, Castellsagué X, Díaz M, De Sanjosé S, Hammouda D, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer. 2004;111:278-85.
2. Hildesheim A, Markowitz L, Hernández Ávila M, Franceschi S. Research needs following initial licensure of virus-like particle HPV vaccines. Vaccine. 2006;24 Suppl 3:227-32.
3. De Sanjosé S, Almirall R, Lloveras B, Font R, Díaz M, Muñoz N, et al. Cervical papillomavirus infection in the female population in Barcelona, Spain. Sex Transm Dis. 2003;30:788-93.
4. Clifford G, Gallus S, Herrero R, Muñoz, Snijders P, Vaccarella S, et al. Worlwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet. 2005;366:991-8.
5. Del Amo Valero J, González Blázquez C, Losana Baro J. La infección por virus del papiloma humano en poblaciones a alto riesgo de cáncer de cuello uterino en España. En: De San José S, García García A, editores. Virus del papiloma humano y cáncer: epidemiología y prevención. Madrid: Sociedad Española de Epidemiología; 2006. p. 73-7.
6. Área de Epidemiología Ambiental y Cáncer. Centro Nacional de Epidemiología. Mortalidad por cáncer y otras causas. España, año 2004 [consultado 27/09/2006]. Disponible en: http://193.146.50.130/htdocs/cancer/mort2004.txt
7. Ponencia de Programas y Registros de Vacunación. Consejo Interterritorial del Sistema Nacional de Salud. Criterios para fundamentar la modificación de los programas de vacunas. 2004 [consultado 04/08/2006]. Disponible en: http://www.msc.es/ciudadanos/proteccionSalud/vacunaciones/docs/ criteriosVacunas.pdf
8. Bottiger M, Forsgren M. Twenty years' experience of rubella vaccination in Sweden: 10 years of selective vaccination (of 12-year-old girls and of women postpartum) and 13 years of a general two-dose vaccination. Vaccine. 1997;15:1538-44.
9. Muñoz N, Bosch X, Garnett G, Patnick J, Sultan C, Watson M. Preventive vaccination against HPV diseases: policy drivers for maximum European public-health benefit. HPV Today 2005 (7):6.
10. Barr E. Record of the meeting of the Advisory Committee on Immunization Practices. February 21-22, 2006. [consultado 04/08/2006]: Disponible en: http://www.cdc.gov/nip/ACIP/minutes/acip_ min_feb06.pdf
11. Winer R, Koutsky L. Human papillomavirus through the ages. J Infect Dis. 2005;191:1787-9.
12. Lowndes C. Vaccines for cervical cancer. Epidemiol Infect. 2006;13:1-12.
13. Lowy D. The biology of HPV. Record of the meeting of the Advisory Committee on Immunization Practices. February 21-22, 2006 [consultado 05/08/2006]. Disponible en: http://www.cdc.gov/nip/ACIP/slides/mtg-slides-feb06. htm#HPV
14. Centers for Disease Prevention and Control. Press release. CDC's Advisory Committee recommends human papillomavirus virus vaccination. June 29, 2006 [consultado 10/08/2006]. Disponible en: http://www.cdc.gov/od/oc/media/pressrel/ r060629.htm (consultado 10-08-2006)
15. Committee on Adolescent Health Care and the ACOG Working Group on Immunization. Human papillomavirus vaccination. Obstet Gynecol. 2006;108:699-705.
16. Carter J, Koutsky L, Hughes J, Kuang Lee S, Kuypers J, Kiviat N, et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis. 2000;181: 1911-9.
17. Mao C, Koutsky L, Ault K, Wheeler C, Brown D, Wiley D, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia. Obstet Gynecol. 2006;107:18-27.
18. Cuzick J, Mayrand M, Ronco G, Snidjers P, Wardle J. New dimensions in cervical cancer screening. Vaccine. 2006;24 Suppl 3:90-7.
19. Stoler M. HPV in screening and triage. HPV testing: if it's not clinically valid it's dangerous. HPV Today. 2006 (9):4-5.
20. Burd E. Human papillomavirus and cervical cancer. Clin Microbiol Rev. 2003;16:1-17.
21. Vaccines and Related Biological Products Advisory Committee. Briefing document. Presented to VRBPAC on 18-May-2006. Disponible en: http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4222B1.pdf
22. Vaccines and Related Biological Products Advisory Committee. Background Document. Gardasil VPH quadrivalent vaccine. May 18, 2006 VRBPAC Meeting. Disponible en: www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4222B3.pdf
23. Harper L, Franco E, Wheeler C, Moscicki A, Romanowski B, Roteli-Martins C, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up of a randomised control trial. Lancet. 2006;367:1247-55.
24. Villa L, Costa R, Petta C, Andrade R, Aula K, Giuliano A, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11,16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005; 6:271-8.
25. Stanley M. Immune responses to human papillomavirus. Vaccine. 2006;24 Suppl 1:16-22.
26. Villa L, Ault K, Giuliano A, Costa R, Petta C, Andrade R, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16 and 18. Vaccine. 2006;24:5571-83.
27. Poland G, Jacobson R, Koutsky L, Tamms G, Railkar R, Smith J, et al. Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16: a randomized controlled clinical trial. Mayo Clin Proc. 2005;80:601-10.
28. Barr E. ACIP Meeting presentation slides. June 29-30, 2006 [consultado 10/08/2006]. Disponible en: http://www.cdc.gov/nip/ACIP/slides/mtg-slides-jun06. htm#HPV
29. Giannini S, Hanon E, Moris P, Van Mechelen M, Morel S, Dessy F, et al. Enhanced humoral and memory B cellular immunity using HPV 16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine. 2006;24:5937-49.
30. Christensen N, Reed C, Cladel N, Han R, Kreider J. Immunization with virus like particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. J Virol. 1996;70:960-5.
31. European Medicines Agency. European public assessement reports. Gardasil. Scientific discussion [consultado 05/10/2006]. Disponible en: http://www.emea.eu.int/humandocs/Humans/EPAR/gardasil/gardasil.htm
32. Advisory Committee on Immunization Practices. June 2006 ACIP Meeting presentation slides. VPH vaccine. VFC resolution [consultado 10/08/2006]. Disponible en: http://www.cdc.gov/nip/ACIP/slides/jun06/HPV-7-calugar.pdf
33. Stanley M, Lowy D, Frazer I. Prophylactic HPV vaccines: underlying mechanisms. Vaccine. 2006;24 Suppl 3:106-13.
34. Block S, Nolan T, Sattler C, Barr E, Giacoletti K, Merchant C, et al. Comparison of the immunogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and females adolescents and young adult women. Pediatrics. 2006;118:2135-45.
35. Barnabas R, Laukkanen P, Koskela P, Kontula O, Lehtinen M, Garnett G. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analysis. PLoS Medicine. 2006;3:e138.
36. Taira A, Neukermans C, Sanders G. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis. 2004;10:1915-23.
37. Goldie S. Decision science in medicine and public health. HPV Today. 2006 (9):1-4.
38. Should VPH vaccines be mandatory for all adolescents? [editorial]. Lancet. 2006;368:1212.
39. Hughes J, Garnett G, Koutsky L. The theoretical population-level impact of a prophylactic human papilloma virus vaccine. Epidemiology. 2002; 13:631-9.
40. Merck & Co., Inc. Gardasil. Prescribing information [consultado 10/09/2006]. Disponible en: http://www.merck. com/product/usa/pi_circulars/g/ gardasil/gardasil_pi.pdf
41. European Medicines Agency. European public assessement reports. Gardasil. Product information [consultado 05/10/2006]. Disponible en: http://www.emea.eu.int/humandocs/Humans/EPAR/gardasil/gardasil.htm
42. Waller J, McCaffery K, Forrest S, Szarewski A, Cadman L, Wardle J. Awareness of human papillomavirus among women attending a well woman clinic. Sex Transm Infect. 2003;79:320-2.
43. Brabin L, Roberts S, Farzaneh F, Kitchener H. Future acceptance of adolescent human papillomavirus vaccination: a survey of parental attitudes. Vaccine. 2006;24:3087-94.
44. Dempsey A, Zimmet G, Davis R, Koutski L. Factors that are associated with parental acceptance of human papillomavirus vaccines: a randomized intervention study of written information about HPV. Pediatrics. 2006;117:1486-93.
45. Franco E, Cuzick J, Hildesheim A, De Sanjosé S. Issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine. 2006;24 Suppl 3:171-7.
46. Markowitz L. ACIP Meeting presentation slides. June 29-30, 2006 [consultado 10/08/2006]. Disponible en: http://www.cdc.gov/nip/ACIP/slides/ jun06/HPV-6-markowitz.pdf
47. Centers for Disease Control and Prevention. ACIP minutes meeting. June 29-30, 2006 [consultado 10/09/2006]. Disponible en: http://www.cdc.gov/nip/ACIP/ minutes/acip-min-jun06.pdf
48. Cox T. HPV testing combined with citology in primary cervical screening. HPV Today 2005 (6):4-5.
49. Wright T, Bosch X, Franco E, Cuzick J, Schiller J, Garnett G, et al. HPV vaccines and screening in the prevention of cervical cancer; conclusions from a 2006 workshop of international experts. Vaccine. 2006;24 Suppl 3:251-61.
50. IARC. Monographs on the evaluation of carcinogenic risks to humans. Vol. 90. Human papillomavirus. Lyon: IARC; 2005.